SEATTLE and VANCOUVER, BC, Sept.
10, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc.
(NASDAQ: ACHV), a clinical-stage pharmaceutical company committed
to the global development and commercialization of cytisinicline
for smoking cessation, today announced that cytisinicline data will
be featured in two presentations on Friday,
September 18th, at the SRNT-E virtual
conference. Both presentations evaluate positive findings
from studies comparing cytisinicline to varenicline (Chantix®).
- "Cytisine's Lower Potency at 5-HT3 Receptors May
Explain its Lower Incidence of Nausea and Vomiting than
Varenicline", presented by Achieve's Chief Scientific Officer,
Dr. Anthony Clarke, at 1:00PM CET.
- "Is Cytisine At Least as Effective as Varenicline for
Smoking Cessation? Findings from a Non-Inferiority Trial in
Indigenous New Zealanders and their Extended Family", presented
by the RAUORA study Primary Investigator, Dr. Natalie Walker, at 4:15PM
The presentations will be followed by a 30-minute live Q&A
session with the authors and additional details can be found at
About Achieve and Cytisinicline
Tobacco use is
currently the leading cause of preventable death and is responsible
for more than eight million deaths annually worldwide1.
It is estimated that 28.7% of cancer deaths in the U.S. are
attributable to cigarette smoking2. Achieve's focus is
to address the global smoking health and nicotine addiction
epidemic through the development and commercialization of
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
As an approved, branded product in Central and Eastern Europe for more than two decades, it
is estimated that over 20 million people have used cytisinicline to
help combat nicotine addiction.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, the timing and nature of
cytisinicline clinical development activities, the potential market
size for cytisinicline and the effectiveness and potential uses and
benefits of cytisinicline. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. Achieve may not actually achieve its plans or product
development goals in a timely manner, if at all, or otherwise carry
out its intentions or meet its expectations or projections
disclosed in these forward-looking statements. These statements are
based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions that
could cause actual results to differ materially from those
described in the forward-looking statements, including, among
others, the risk that cytisinicline may not demonstrate the
hypothesized or expected benefits; the risk that cytisinicline may
not be effective in treating a larger breadth of diseases and
addictions; the risk that Achieve may not be able to obtain
additional financing to fund the development of cytisinicline; the
risk that cytisinicline will not receive regulatory approval or be
successfully commercialized; the risk that new developments in the
smoking cessation landscape require changes in business strategy or
clinical development plans; the risk that Achieve's intellectual
property may not be adequately protected; general business and
economic conditions; impacts from the COVID-19 pandemic; and the
other factors described in the risk factors set forth in Achieve's
filings with the Securities and Exchange Commission from time to
time, including Achieve's Annual Reports on Form 10-K and Quarterly
Reports on Form 10-Q. Achieve undertakes no obligation to update
the forward-looking statements contained herein or to reflect
events or circumstances occurring after the date hereof, other than
as may be required by applicable.
Investor Relations Contact
(415) 375-3340 ext. 4
Chantix® is a registered trademark of Pfizer Inc.
1 World Health Organization. WHO Report on the Global
Tobacco Epidemic, 2019. Geneva:
World Health Organization, 2017
2 Annals of Epidemiology, Volume 25, Issue 3, 179 -
View original content to download
SOURCE Achieve Life Sciences, Inc.